Hepatitis Forums
Hepatitis C Main Forums => Hepatitis C Research News & Studies => Topic started by: Hep Editors on October 23, 2019, 10:32:15 am
-
The Food and Drug Administration (FDA) has granted a new approval of AbbVie’s Mavyret (glecaprevir/pibrentasvir) that shortens treatment from 12 to eight weeks for those with all six genotypes of hepatitis C virus (HCV) who have not been treated previously. The new drug indication applies to adults and to children who are at least 12 years old or weigh at least 99 pounds and to those without cirrhosis or who have compensated cirrhosis, the milder form of the severe liver disease.
Mavyret was first approved in 2017.
The new indication for Mavyret makes it the first regimen approved for an eight-week course among treatment first-timers and certain children and adolescents with genotypes 1 through 6 of HCV who have compensated cirrhosis or who do not have cirrhosis.
Read more...
https://www.hepmag.com/article/fda-oks-8-weeks-mavyret-hep-c-treatment-firsttimers